(22419) A randomized, double-blind, placebo-controlled, parallel group Phase 2a study with an extension phase to evaluate the efficacy and safety of BAY 3401016 in participants aged 18 to 45 with Alport syndrome
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Decision date
05/12/2025
Enrollment target
31
Sites
Spain, Italy, Poland, Czechia, Germany, Portugal, France
Condition studied
Chronic kidney disease, Alport Syndrome
Investigational medicinal product(s)
Placebo to BAY 3401016BAY 3401016
Eligibility
Age group
18-64 years
Sex
Female, Male
Primary endpoint
Mean UACR ratio to baseline averaged over 16, 20 and 24 weeks of treatment
Endpoint detail
Number of participants with TEAEs and TESAEs
Official registry record
This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.